Banking on biomarkers for synthetic lethality

How Repare’s biomarker-first approach could differentiate its synthetic lethal cancer programs

Repare thinks its biomarker-first approach could be a key differentiator for its synthetic lethal cancer drug programs. The company is collaborating with test developers ahead of time to recruit patients poised to benefit.

Losing function in two or more genes that have a synthetic lethal relationship triggers cell death,

Read the full 493 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE